SCHEMBL981900

SCHEMBL981900

NNC(=O)Cc1ccc2nsnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
AOC2 O75106 3/20 0.43
PTPN11 Q06124 2/20 0.42
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
AOC3 Q16853 2/20 0.40
POLB P06746 2/20 0.40
HPGD P15428 1/20 0.40
PTPN1 P18031 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
BLM P54132 2/20 0.38
APAF1 O14727 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982967 0.80 ALDH1A1 (0.50) KDM4EPTPN11ALDH1A1L3MBTL1GAA
SCHEMBL2495821 0.79 ECE2 (0.54) KDM4ECYP1A2CYP3A4CYP2C9AOC2
SCHEMBL29069425 0.75 NPC1 (0.62) KDM4ECYP3A4PTPN11ALDH1A1L3MBTL1
SCHEMBL15941094 0.74 KDM4E (0.44) KDM4EPTPN11ALDH1A1L3MBTL1GAA
SCHEMBL11796135 0.74 AOC2 (0.66) CYP1A2CYP3A4CYP2C9AOC2GAA
SCHEMBL8724132 0.74 PTPN11 (0.48) KDM4ECYP1A2CYP3A4PTPN11ALDH1A1
SCHEMBL981757 0.74 KMT2A (0.60) KDM4ECYP1A2CYP3A4CYP2C9ALDH1A1
SCHEMBL2491605 0.73 RAB9A (0.57) KDM4ECYP1A2CYP3A4CYP2C9ALDH1A1
SCHEMBL6718146 0.72 MAPT (0.59) KDM4ECYP1A2CYP3A4PTPN11ALDH1A1
SCHEMBL6718144 0.72 MAPT (0.59) KDM4ECYP1A2CYP3A4PTPN11ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US disclosed
WO-2007019933-A1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 KDM4E 1005/4885CYP1A2 437/4885CYP3A4 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.